All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR).
UBX1325 leads to a decrease in the anti-apoptotic Bcl-xL:Bim complex in retina by intravitreal (IVT) injection administration in oxygen induced retinopathy (OIR) C57BL/6 mice model. UBX1325 can cause a decrease in retinal vascular permeability and promote retinal neovascularization in streptozotocin (STZ)-induced retinopathy mice model.
| Molecular Weight | 1159.69 |
| Formula | C53H59ClF3N6O10PS3 |
| CAS Number | 2271269-01-1 |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Jannah Waled Hassan, et al. Front Pharmacol. Senolytics in the treatment of diabetic retinopathy
| Related Bcl-2 Products |
|---|
| ABBV-467
ABBV-467 is a selective MCL-1 inhibitor (Ki: <0.01 nM). |
| WEHI-539
WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM. |
| (Rac)-Lisaftoclax
(Rac)-Lisaftoclax ((Rac)-APG-2575) is a Bcl-2 inhibitor that can be uesd for hematologic malignancy research. |
| BcI-2/BcI-xI ligand 1
BcI-2/BcI-xI ligand 1 is a BcI-2/BcI-xI ligand, and can be used for synthesis of PROTAC BcI-2/BcI-xI Degrader-1. |
| AZD-5991 (S-enantiomer)
AZD-5991 S-enantiomer is the less active enantiomer of AZD-5991. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
